47,346 Shares in United Therapeutics Corporation $UTHR Purchased by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 47,346 shares of the biotechnology company’s stock, valued at approximately $25,653,000.

Other institutional investors have also bought and sold shares of the company. Avoro Capital Advisors LLC boosted its holdings in shares of United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after buying an additional 383,838 shares during the last quarter. Wellington Management Group LLP grew its position in United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after buying an additional 1,042,711 shares during the period. AQR Capital Management LLC increased its holdings in United Therapeutics by 29.9% during the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after buying an additional 295,221 shares during the last quarter. Janus Henderson Group PLC increased its holdings in United Therapeutics by 8.9% during the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after buying an additional 70,829 shares during the last quarter. Finally, Norges Bank bought a new stake in United Therapeutics in the fourth quarter worth about $293,418,000. Institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $547.62, for a total value of $5,202,390.00. Following the transaction, the chief executive officer owned 40,513 shares in the company, valued at approximately $22,185,729.06. The trade was a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $546.28, for a total value of $5,462,800.00. Following the transaction, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,311,581.28. This represents a 34.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 434,275 shares of company stock worth $234,984,268. 8.60% of the stock is owned by insiders.

United Therapeutics Stock Down 1.5%

NASDAQ UTHR opened at $521.00 on Friday. The stock’s 50-day simple moving average is $533.74 and its two-hundred day simple moving average is $537.53. United Therapeutics Corporation has a twelve month low of $302.19 and a twelve month high of $609.35. The company has a market capitalization of $22.35 billion, a price-to-earnings ratio of 18.64, a PEG ratio of 1.79 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. During the same period last year, the business earned $6.41 earnings per share. The business’s quarterly revenue was down 1.9% on a year-over-year basis. On average, equities analysts expect that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on UTHR shares. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Royal Bank Of Canada lowered their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Morgan Stanley set a $515.00 price target on United Therapeutics in a research report on Thursday, August 6th. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Bank of America lowered their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $646.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.